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Published clinical trials in patients with ischemic diseases show limited benefit
of adult stem cell-based therapy, likely due to their restricted plasticity and com-
mitment towards vascular cell lineage. Here, we have uncovered the potent regen-
erative ability of MesP1/SSEA-1-expressing cardiovascular progenitors enriched
from human embryonic stem cells (hESC). Injection of only 104 hESC-derived
SSEA-1+/MesP1+ cells, or their progeny obtained after treatment with VEGF-A or
PDGF-BB, was effective enough to enhance post-ischemic revascularization in
immunodeficient mice with critical limb ischemia (CLI). However, the rate of
incorporation of hESC-derived SSEA-1+/MesP1+ cells and their derivatives in
ischemic tissues was modest. Alternatively, these cells possessed a unique miR-21
signature that inhibited PTEN thereby activating HIF-1α and the systemic release
of VEGF-A. Targeting Dicer or miR-21 limited cell survival in vivo and inhibited
their pro-angiogenic capacities both in the Matrigel model and in mice with CLI.
Interestingly, we observed an impaired post-ischemic angiogenesis in miR-21
deficient mice suggesting an unrestricted role of miR-21 in this regenerative envi-
ronment. Notably, amongst the inflammatory cell population, miR-21 was highly
expressed in circulating and infiltrated monocytes where it targeted PTEN/HIF-
1α/VEGF-A signaling. As a result, miR-21 deficient mice displayed an impaired
number of infiltrated monocytes and a defective angiogenic phenotype that could
be partially restored by retransplantation of bone marrow-derived cells from wild-
type littermates. Hence, hESC-derived SSEA-1+/MesP1+ cells progenitor cells are
powerful key integrators of therapeutic angiogenesis in ischemic milieu and miR-
21 is instrumental in this process as well as in the orchestration of post-ischemic
vessel growth.
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Background: Prokineticin receptor-1 (PKR1), signals play critical roles in
heart and kidney functions. In particular, the systemic mutation of this
receptor results in thinning of the myocardium and hypoplastic kidney. How-
ever, the molecular and cellular mechanisms controlled by PKR1 signaling in
this process are unclear.
Methods and Results: Here, we analyze a tissue-restricted mutations of the
PKR1 gene in the proepicardial lineages (Gata5 and Wt1), and we show that
PKR1 signaling in the proepicardium and its derivatives is required for proper car-
diac and renal morphogenesis. Neonatal mutant mice display impaired prolifera-
tion of epicardial-derived cells in their heart and kidneys. Moreover, we detect
defective coronary and renal arteriogenesis associated with PKR1 deficiency. Epi-
cardial development is dramatically impaired in mutant mice, including failed
expansion of the subepicardial space, blunted invasion of the myocardium, and
impaired differentiation of epicardium-derived cells into coronary endothelial and
smooth muscle cells. Abnormal mitochondria, lipid accumulation in mutant car-
diomyocytes leads to lower contractile response to dobutamine. Impaired prolifer-
ation was observed in both Gata5 and WT1 but apoptosis was observed only WT1
lieage. Adult mutant hearts had abnormal rhythmicity and impaired systolic func-
tions. Hypoplastic kidneys at the neonatal mutants were accompanied with defi-
cient glomerular angiogenesis. Outgrown cell from kidney explants had a
defective vasculogenic cell differentiation. Atrophy and dilated glomerular struc-
ture, abnormal mitochondria, lipid deposition and apoptosis were observed in the
adult mutant kidney.
Conclusions: Our findings provide a mechanistic insight into the roles of
PKR1 signaling in heart and kidney disorders controlling the maturation of
epicardial-derived cell and differentiation in a cell autonomous fashion and
affecting cellular communications in a paracrine fashion. Our mouse models
recapitulate the complex human heart-kidney disorders.
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Coronary vasculature is required to maintain cardiomyocyte survival, via
delivery of oxygen and nutrients, and consequently myocardial architecture and
cardiac function. Ischemic heart disease following myocardial infarction causes
irreversible cell loss and scaring and is a major cause of morbidity and mortality.
Revascularization of injured, ischemic and regenerating organs is essential to
restore organ function and requires the formation of new vessels by the mecha-
nisms of vasculogenesis, angiogenesis or arteriogenesis. With the objective of
studying vascular remodeling during myocardial infarction (MI), we have per-
formed permanent left coronary ligation on Connexin40-GFP (Cx40GFP/+) mice.
Cx40 encodes a gap junction protein and is expressed in endothelial cells of large
vessels. In the heart, Cx40-GFP expression is detected in coronary arteries but not
in veins, capillaries or endocardium. After two weeks of ligation, MI was detected
in left ventricle by echocardiography and anatomical examination of these hearts
revealed the presence of an extensive network of GFP-positive vasculature within
the infarct area. These vessels follow a tortuous route in the remaining ventricular
wall and some communicate with the left ventricular lumen forming a crater cov-
ered with GFP and VEGF-R2 positive endothelial cells at the endocardial surface.
To determine whether these vessels result from neo-vascularization or coronary
artery remodeling, we carried out genetic lineage tracing of coronary endothelial
cells using an inducible Cx40-cre allele. Our results show that GFP positive endo-
thelial cells forming the endocardial carters are not always derived from pre-
existing coronary arteries, suggesting that endocardium may also contribute to the
generation of new vessels during vascular remodeling in the adult heart by angio-
genesis.
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Objective: Prokineticins are potent angiogenic peptides that bind to two G
protein-coupled receptors to initiate their biological effects. We previously
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have shown that prokineticin receptor-1 (PKR1) signaling contributes to car-
diomyocyte survival or repair in myocardial infarction. Here, we discovered
the first non-peptidic PKR1 agonists and examined their effects in mice model
of heart diseases.
Methods and results: Herein we identify a selective PKR1 agonist both in
vitro and in vivo, utilizing GPCR structure-based virtual screening approach.
High Throughput Docking was carried out by GOLD using homology model
of PKR1. Asinex gold collection 3D chemical databese (250,000 compounds)
was screened by the docking protocol. We provided a strategy with a high
potential for in silico identifying one agonist hit. We present here IS20, the
first synthetic PKR1 agonist that induces angiogenesis in the presence of
PKR1 on the endothelial cells seeded on matrigel. IS20 reduced doxorubicin
cytotoxicity in H9C2 cells. IS20 promotes mouse epicardial progenitor cell
differentiation into endothelial cells. In vivo IS20 activates Akt in mice heart.
IS20 treatment of mice after coronary ligation reduces mortality by 30%.
Conclusion: This study identifies a non-peptidic PKR1 agonist as thera-
peutic target holding promise for treatment of heart diseases.
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Lack of post-ischemic revascularization is a major complication in diabetic
patients. The kallikrein-kinin system (KKS) could play a role in post-ischemic
neovascularization in non-diabetic conditions. The aim of this study was to
potentialized the post-ischemic neovascularization process in diabetic mice via
specific activation of bradykinin receptors (B1R or B2R) of KKS.
Hindlimb ischemia was induced in normo or hyperglycemic mice by liga-
tion of the right femoral artery. Mice were then treated or not with specific
B1R or B2R agonists (720nmol/kg.d-1). Fourteen days after ischemia, neovas-
cularization was analyzed using angiography, capillary density analysis, foot
blood perfusion measurement and biochemistry. At the end of treatment, vas-
cular and capillary density and skin foot blood flow were significantly
decreased in diabetic condition. In contrast, treatment of diabetic mice with
the B1R or B2R agonist restored post-ischemic neovascularization process to
normal levels of vascular density (+45% for B1R, p<0.01 and 40% for B2R
p<0.01), capillary density (+64% for B1R, p<0.01 and 66% for B2R, p<0.01)
and foot blood perfusion (40% for B1R; p<0.01 and 30% for B2R, p<0.01)
when compared with untreated diabetic mice. These beneficial effects were
associated with an increase in macrophages infiltration in ischemic tissue and
an increase in VEGF protein levels in gastrocnemius muscle. Moreover, in
diabetic mice, 7 days of treatment with B2R agonist, but not B1R agonist, sig-
nificantly increased MCP-1 mRNA expression in muscle (+95%, p<0,01),
MCP-1 level in plasma (+18.5%, p<0.05) and number of circulating mono-
cytes.
KKS modulation via B1R or B2R agonist can restore post-ischemic neo-
vascularization in diabetic mice and may represent a new therapeutic strategy
in this context.
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Red wine polyphenols compounds (RWPC) are known to protect against
deleterious effects of cardiac and cerebral ischemia. However, they exert dif-
ferent effect depending on the dose on post-ischemic neovascularisation. Low
dose (0.2mg/kg/d) promotes angiogenesis, whereas high dose (20mg/kg/d) has
anti-angiogenic property. The vascular effect of RWPC is mediated through
the activation of a redox-sensitive pathway, mitochondrial biogenesis and the
activation of α isoform of the estrogen receptor (ERα). Here we evaluate the
implication of ERα on angiogenic properties of RWPC. Using ovariectomized
mice lacking ERα treated with high dose of RWPC after hindlimb ischemia,
we examined blood flow reperfusion, vascular density, nitric oxide (NO) pro-
duction, expression and activation of proteins involved in angiogenic process
(eNOS, cav-1, VEGF) and muscle energy sensing network proteins (Sirt-1,
AMPK and PGC-1). High dose of RWPC treatment reduced both blood flow
and vascular density in muscles of mice expressing ERα. These effects were
associated with reduced NO production resulting from diminished activity of
eNOS. Surprisingly, high dose of RWPC increased blood flow and capillary
density in mice lacking ERα. This effect is accompanied with increased NO
pathway and production as well as VEGF expression. Interestingly, RWPC
was able to activate Sirt-1, AMPK and PGC-1 in hindlimb from both strains.
Altogether, the results highlight a pro-angiogenic property of RWPC via an
ERα-independent mechanism that is associated with an up-regulation of
energy sensing network proteins of the Sirt-1, PGC-1 network. This study
depicts a novel way by which polyphenols may represent a therapeutic
approach to treat pathologies associated with failed vascularisation.
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